229971-81-7
基本信息
N-钙粘蛋白拮抗剂
化合物EXHERIN
(4R,7S,10S,13S,16R)-13-((1H-咪唑-5-基)甲基)-16-乙酰氨基-7-异丙基-10-甲基-6,9,12,15-四氧基-1,2-二硫基-5,8,11,14-四氮杂环庚烷-4-酰胺
Exherin
CS-2142
Exherin TFA
ADH-1 Exherin
Exherin (ADH-1)
L-Cysteinamide, N-acetyl-L-cysteinyl-L-histidyl-L-alanyl-L-valyl-, cyclic (1→5)-disulfide
物理化学性质
| 沸点 | 1183.4±65.0 °C(Predicted) |
| 密度 | 1.40±0.1 g/cm3(Predicted) |
| 储存条件 | Keep in dark place,Sealed in dry,Store in freezer, under -20°C |
| 溶解度 | DMSO:2.2(Max Conc. mg/mL);3.86(Max Conc. mM) |
| 酸度系数(pKa) | 13.13±0.70(Predicted) |
| 形态 | A solid |
| 颜色 | White to off-white |
| InChIKey | FQVLRGLGWNWPSS-BXBUPLCLSA-N |
| SMILES | S1SC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C1)C(=O)N)C(C)C)C)Cc2[nH]cnc2)NC(=O)C |
安全数据
| WGK Germany | WGK 3 |
| 存储类别 | 11 - Combustible Solids |
N-钙粘蛋白拮抗剂价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2026/06/05 | HY-13541 | (4R,7S,10S,13S,16R)-13-((1H-咪唑-5-基)甲基)-16-乙酰氨基-7-异丙基-10-甲基-6,9,12,15-四氧基-1,2-二硫基-5,8,11,14-四氮杂环庚烷-4-酰胺 ADH-1 | 229971-81-7 | 5mg | 1000元 |
| 2026/06/05 | HY-13541 | (4R,7S,10S,13S,16R)-13-((1H-咪唑-5-基)甲基)-16-乙酰氨基-7-异丙基-10-甲基-6,9,12,15-四氧基-1,2-二硫基-5,8,11,14-四氮杂环庚烷-4-酰胺 ADH-1 | 229971-81-7 | 10mg | 1700元 |
| 2026/06/05 | HY-13541 | (4R,7S,10S,13S,16R)-13-((1H-咪唑-5-基)甲基)-16-乙酰氨基-7-异丙基-10-甲基-6,9,12,15-四氧基-1,2-二硫基-5,8,11,14-四氮杂环庚烷-4-酰胺 ADH-1 | 229971-81-7 | 25mg | 3100元 |
常见问题列表
ADH-1 (0.2 mg/mL) blocks collagen I-mediated changes in pancreatic cancer cells, and is highly effective at preventing cell motility that is induced by expression of N-cadherin. ADH-1 (0, 0.1, 0.2, 0.5 and 1.0 mg/mL) induces apoptosis in a dose-dependent and N-cadherin-dependent manner.
ADH-1 (50 mg/kg) significantly prevents tumor growth and metastasis in a mouse model for pancreatic cancer. ADH-1 prevents tumor cell invasion and metastasis in an orthotopic model for pancreatic cancer using N-cadherin overexpressing BxPC-3 cells. ADH-1, at the dosages evaluated, does not display either antiangiogenic activity in a rat aortic ring assay or antitumor potential in a PC3 subcutaneous xenograft tumor model. ADH-1 (10 mL/kg, i.p.) augmentation of melanoma tumor growth is overcome through its ability to make regionally infused melphalan more effective. ADH-1 mediated augmentation of melanoma tumor growth is not altered by regionally infused temozolomide. In A375, but not DM443 xenografts, ADH-1 treatment increases phosphorylation of AKT at serine 473. ADH-1 slightly diminishes N-cadherin expression in both xenografts.